×
Pour une meilleure utilisation, nous vous conseillons d’activer Javascript dans votre navigateur.
Cyclosporin A anticorps
CsA
Reactivité: Chemical
EIA
Hôte: Souris
Monoclonal
4A3 (CSZ-22)
unconjugated
Détail du produit anti-Cyclosporin A anticorps
(cache)
Antigène
Voir toutes Cyclosporin A (CsA) Anticorps
Cyclosporin A (CsA)
Reactivité
Toutes les réactivités sur Cyclosporin A Anticorps
Chemical
Hôte
Toutes les hôtes sur Cyclosporin A Anticorps
Souris
Clonalité
Toutes les clonalités sur Cyclosporin A Anticorps
Monoclonal
Conjugué
Tous les conjugués à travers Cyclosporin A Anticorps
Cet anticorp Cyclosporin A est non-conjugé
Application
Tous les applications à travers Cyclosporin A Anticorps.
Enzyme Immunoassay (EIA)
Purification
Affinity Chromatography on Protein G.
Immunogène
Cyclosporin A conjugated to an HMW carrier
Clone
4A3 (CSZ-22)
Isotype
IgG1
Top Product
Discover our top product CsA Anticorps primaire
Alternatives
(show)
Information d'application
(cache)
Indications d'application
ELISA. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Stockage
(cache)
Concentration
1.0 mg/mL
Buffer
PBS, pH 7.5 containing 0.09 % Sodium Azide as preservative.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Conseil sur la manipulation
Avoid repeated freezing and thawing.
Stock
4 °C/-20 °C
Stockage commentaire
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Détails sur Cyclosporin A
(cache)
Antigène
Cyclosporin A (CsA)
Autre désignation
Cyclosporin A (CsA Produits )
Classe de substances
Chemical
Sujet
Cyclosporin is used to prevent rejection following solid organ and bone marrow transplantation . It has been estimated that cyclosporine is given to more than 90?% of children who have received a kidney transplant in the United States. In addition, the ability of cyclosporin to inhibit T-cell activation has been shown to have a role in the treatment of diseases such as nephrotic syndrome, refractory Crohn's disease and ulcerative colitis, biliary cirrhosis, aplastic anemia, rheumatoid arthritis, myasthenia gravis, and dermatomyositis.
Vus récemment
(cache)